Executive Vice President and Worldwide Chairman, Innovative Medicine, Johnson & Johnson
Appears in 1 story
Leading J&J's immunology commercial strategy
For two decades, the most effective treatments for moderate-to-severe psoriasis required needles — self-injected drugs or clinic infusions that many patients refused or abandoned. On March 18, 2026, the Food and Drug Administration (FDA) approved ICOTYDE, a once-daily pill that blocks the interleukin-23 (IL-23) receptor with the precision of an injectable biologic. In clinical trials of roughly 2,500 patients, about 70 percent achieved clear or almost clear skin at 16 weeks, with side effects within 1.1 percentage points of a placebo.
Updated 3 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
